Suzanne Bruhn

Dr. Bruhn is an accomplished life sciences executive and brings expertise in R&D, commercialization, and executive leadership to this role. Dr. Bruhn is the president and CEO, and Director of Tiaki Therapeutics, a privately held biotech company with a platform focused on identifying drug targets for neuroinflammation in neurodegenerative diseases. Before that, she served as president and CEO of Proclara Biosciences, a clinical-stage company pioneering a novel approach to treat disorders of protein misfolding including Alzheimer’s and Parkinson’s Disease, as well as orphan amyloidosis. Prior to that she served as president and CEO of Promedior, Inc., a clinical-stage immunotherapy company developing targeted therapeutics to treat fibrosis. Prior to Promedior, she spent 13 years at Shire Human Genetic Therapies (HGT), a division of Shire PLC, specializing in the development and commercialization of treatments for orphan diseases, where she held a series of positions of increasing responsibility before serving as senior vice president of strategic planning and program management. During her tenure at Shire HGT, Dr. Bruhn was responsible for establishing the program management function, driving strategic planning and portfolio management, and for global regulatory affairs. Prior to her time at Shire, Dr. Bruhn held various positions at Cytotherapeutics, Inc., a biotechnology company. Dr. Bruhn currently sits on the board of directors of Pliant Therapeutics (NASDAQ: PLRX), Travere Therapeutics (NASDAQ: TVTX) and Vigil Neuroscience (NASDAQ: VIGL). Dr. Bruhn holds a Bachelor’s degree in chemistry from Iowa State University, a Ph.D. in chemistry from the Massachusetts Institute of Technology and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School.